哌甲酯治疗注意缺陷多动障碍儿童青少年的长期安全性:ADDUCE研究2年结果
ADDUCE研究是一项在5个欧洲国家27个中心开展的自然主义纵向对照研究,纳入6-17岁儿童青少年共1410例,分为哌甲酯组、未用药ADHD组和无ADHD对照组。经倾向性评分控制混杂后,随访24个月未发现哌甲酯对身高增长速度、精神或神经不良事件有显著影响,但哌甲酯组脉率和收缩压、舒张压均高于未用药ADHD组,需定期监测。
要点
- 随访24个月,哌甲酯组与未用药ADHD组身高速度SD评分差异无统计学意义。
- 哌甲酯组脉率及收缩压、舒张压均高于未用药ADHD组,需定期监测。
- 研究期间未报告严重不良事件,支持哌甲酯2年治疗总体安全。
核心结论
- 哌甲酯治疗2年总体安全,未发现支持其导致生长减弱的证据。
- 哌甲酯相关脉率和血压变化虽相对较小,但仍需定期监测。
研究设计与样本
- 自然主义纵向对照研究,纳入欧洲5国27个儿童青少年精神卫生中心的6-17岁参与者。
- 共纳入1410例:哌甲酯组756例、未用药ADHD组391例、无ADHD对照组263例。
- 主要结局为身高速度SD评分,依据至少连续两次身高测量并按同年龄同性别参考人群标准化。
主要发现
- 哌甲酯组与未用药ADHD组相比,精神或神经不良事件风险未见明显增加。
- 治疗24个月后,哌甲酯组脉率及收缩压、舒张压均高于未用药ADHD组。
- 研究期间未报告严重不良事件。
关键数值与推荐
- ADHD诊断由合格临床医生依据DSM-IV标准作出。
- 既往使用过任何ADHD药物者被排除,但既往或当前使用其他精神药物者仍可入选。
临床怎么用
- 哌甲酯长期治疗期间应定期监测脉率和血压。
- 现有证据不支持将生长减速作为哌甲酯2年治疗的预期不良反应。
局限性
- 原文未报告针对生长、精神神经及心血管结局以外的长期安全性数据分析。
- 原文未报告盲法设置及失访处理等偏倚控制细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methylphenidate is the most frequently prescribed medication for the treatment of ADHD in children and adolescents in many countries. Although many randomised controlled trials support short-term efficacy, tolerability, and safety, data on long-term safety and tolerability are scarce. The aim of this study was to investigate the safety of methylphenidate over a 2-year period in relation to growth and development, psychiatric health, neurological health, and cardiovascular function in children and adolescents. METHODS: We conducted a naturalistic, longitudinal, controlled study as part of the ADDUCE research programme in 27 European child and adolescent mental health centres in the UK, Germany, Switzerland, Italy, and Hungary. Participants aged 6-17 years were recruited into three cohorts: medication-naive ADHD patients who intended to start methylphenidate treatment (methylphenidate group), medication-naive ADHD patients who did not intend to start any ADHD medication (no-methylphenidate group), and a control group without ADHD. Children with ADHD diagnosed by a qualified clinician according to the DSM-IV criteria and, in the control group, children who scored less than 1·5 on average on the Swanson, Nolan, and Pelham IV rating scale for ADHD items, and whose hyperactivity score on the parent-rated Strengths and Difficulties Questionnaire was within the normal range (<6) were eligible for inclusion. Participants were excluded if they had previously taken any ADHD medications but remained eligible if they had previously taken or were currently taking other psychotropic drugs. The primary outcome was height velocity (height velocity SD score; estimated from at least two consecutive height measurements, and normalised with reference to the mean and SD of a population of the same age and sex). FINDINGS: Between Feb 01, 2012, and Jan 31, 2016, 1410 participants were enrolled (756 in methylphenidate group, 391 in no-methylphenidate group, and 263 in control group). 1070 (76·3%) participants were male, 332 (23·7%) were female, and for eight gender was unknown. The average age for the cohort was 9·28 years (SD 2·78; IQR 7-11). 1312 (93·0%) of 1410 participants were White. The methylphenidate and no-methylphenidate groups differed in ADHD symptom severity and other characteristics. After controlling for the effects of these variables using propensity scores, there was little evidence of an effect on growth (24 months height velocity SD score difference -0·07 (95% CI -0·18 to 0·04; p=0·20) or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group. Pulse rate and systolic and diastolic blood pressure were higher in the methylphenidate group compared with the no-methylphenidate group after 24 months of treatment. No serious adverse events were reported during the study. INTERPRETATION: Our results suggest that long-term treatment with methylphenidate for 2 years is safe. There was no evidence to support the hypothesis that methylphenidate treatment leads to reductions in growth. Methylphenidate-related pulse and blood pressure changes, although relatively small, require regular monitoring. FUNDING: EU Seventh Framework Programme.
引用
- Man KKC, Häge A, Banaschewski T, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. Lancet Psychiatry. 2023. PMID: 36958362. doi:10.1016/S2215-0366(23)00042-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。